Newton Charles W.
- SEC CIK
- 0001866219
In the past year, 2 open-market sale filings worth $11.2K and no purchases.
Current role at each company
- KROS Keros Therapeutics, Inc.Directoras of Aug 20, 2026
- NVAX Novavax IncDirectoras of Jun 23, 2026
- CHRS Coherus Oncology, Inc.Directoras of Jun 9, 2026
- LYEL Lyell Immunopharma, Inc.Chief Financial Officeras of Aug 22, 2025
- TSVT 2seventy bio, Inc.Directoras of May 15, 2025
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $11.2K
- 2 filings
- Net
- −$11.2K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Newton Charles W. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
KROS Keros Therapeutics, Inc.
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 20, 2026 (view filing)4:10 PM ET | Aug 18 | 2 days | Newton Charles W.Director | SSale | −551 | $10.30 | −$5.68K | −4.4%12.1K after | 10b5-1 |
| Jun 15, 2026 (view filing) | Jun 11 | 4 days | Newton Charles W.Director | SSale | −550 | $10.04 | −$5.52K | −4.2%12.7K after | 10b5-1 |
LYEL Lyell Immunopharma, Inc.
Chief Financial Officer3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 22, 2025 (view filing) | Aug 21 | 1 day | Newton Charles W.Chief Financial Officer | SSale | −1.45K | $10.54 | −$15.3K | −8.7%15.3K after | |
| Aug 13, 2025 (view filing) | Aug 11-12 | 2 days | Newton Charles W.Chief Financial Officer | SSale | −267 | $10.43 | −$2.79K | −3.0%8.76K after | 2 lots |
| Mar 18, 2025 (view filing) | Mar 17 | 1 day | Newton Charles W.Chief Financial Officer | PPurchase | +200.0K | $0.56 | +$112.0K | New position200.0K after |